733 related articles for article (PubMed ID: 23108552)
21. The Role of the Cannabinoid System in Pain Control: Basic and Clinical Implications.
Wolf J; Urits I; Orhurhu V; Peck J; Orhurhu MS; Giacomazzi S; Smoots D; Piermarini C; Manchikanti L; Kaye AD; Kaye RJ; Viswanath O
Curr Pain Headache Rep; 2020 Jun; 24(7):35. PubMed ID: 32506272
[TBL] [Abstract][Full Text] [Related]
22. Targeting CB2 receptors and the endocannabinoid system for the treatment of pain.
Anand P; Whiteside G; Fowler CJ; Hohmann AG
Brain Res Rev; 2009 Apr; 60(1):255-66. PubMed ID: 19150370
[TBL] [Abstract][Full Text] [Related]
23. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.
Davis MP
Expert Opin Investig Drugs; 2014 Aug; 23(8):1123-40. PubMed ID: 24836296
[TBL] [Abstract][Full Text] [Related]
24. Additive antiemetic efficacy of low-doses of the cannabinoid CB(1/2) receptor agonist Δ(9)-THC with ultralow-doses of the vanilloid TRPV1 receptor agonist resiniferatoxin in the least shrew (Cryptotis parva).
Darmani NA; Chebolu S; Zhong W; Trinh C; McClanahan B; Brar RS
Eur J Pharmacol; 2014 Jan; 722():147-55. PubMed ID: 24157976
[TBL] [Abstract][Full Text] [Related]
25. In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018.
Gamage TF; Barrus DG; Kevin RC; Finlay DB; Lefever TW; Patel PR; Grabenauer MA; Glass M; McGregor IS; Wiley JL; Thomas BF
Pharmacol Biochem Behav; 2020 Jun; 193():172918. PubMed ID: 32247816
[TBL] [Abstract][Full Text] [Related]
26. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
[TBL] [Abstract][Full Text] [Related]
27. Emerging role of cannabinoids and synthetic cannabinoid receptor 1/cannabinoid receptor 2 receptor agonists in cancer treatment and chemotherapy-associated cancer management.
Shah SA; Gupta AS; Kumar P
J Cancer Res Ther; 2021; 17(1):1-9. PubMed ID: 33723124
[TBL] [Abstract][Full Text] [Related]
28. Cannabis and cannabinoids: pharmacology and rationale for clinical use.
Pertwee RG
Forsch Komplementarmed; 1999 Oct; 6 Suppl 3():12-5. PubMed ID: 10575283
[TBL] [Abstract][Full Text] [Related]
29. Involvement of the CB
Khan MI; Sobocińska AA; Brodaczewska KK; Zielniok K; Gajewska M; Kieda C; Czarnecka AM; Szczylik C
BMC Cancer; 2018 May; 18(1):583. PubMed ID: 29792186
[TBL] [Abstract][Full Text] [Related]
30. Why do cannabinoid receptors have more than one endogenous ligand?
Di Marzo V; De Petrocellis L
Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3216-28. PubMed ID: 23108541
[TBL] [Abstract][Full Text] [Related]
31. The Involvement of the Endocannabinoid System in the Peripheral Antinociceptive Action of Ketamine.
Ferreira RCM; Castor MGM; Piscitelli F; Di Marzo V; Duarte IDG; Romero TRL
J Pain; 2018 May; 19(5):487-495. PubMed ID: 29247851
[TBL] [Abstract][Full Text] [Related]
32. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation.
Di Marzo V
Pharmacol Res; 2009 Aug; 60(2):77-84. PubMed ID: 19559360
[TBL] [Abstract][Full Text] [Related]
33. Cannabis and Endocannabinoid Signaling in Epilepsy.
Katona I
Handb Exp Pharmacol; 2015; 231():285-316. PubMed ID: 26408165
[TBL] [Abstract][Full Text] [Related]
34. Current evidence of cannabinoid-based analgesia obtained in preclinical and human experimental settings.
Lötsch J; Weyer-Menkhoff I; Tegeder I
Eur J Pain; 2018 Mar; 22(3):471-484. PubMed ID: 29160600
[TBL] [Abstract][Full Text] [Related]
35. Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.
McPartland JM; Duncan M; Di Marzo V; Pertwee RG
Br J Pharmacol; 2015 Feb; 172(3):737-53. PubMed ID: 25257544
[TBL] [Abstract][Full Text] [Related]
36. Endocannabinoids in nervous system health and disease: the big picture in a nutshell.
Skaper SD; Di Marzo V
Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3193-200. PubMed ID: 23108539
[TBL] [Abstract][Full Text] [Related]
37. The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9-tetrahydrocannabinol acting through CB1 receptors.
Moreno-Martet M; Feliú A; Espejo-Porras F; Mecha M; Carrillo-Salinas FJ; Fernández-Ruiz J; Guaza C; de Lago E
Mult Scler Relat Disord; 2015 Nov; 4(6):505-11. PubMed ID: 26590655
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.
Zagzoog A; Mohamed KA; Kim HJJ; Kim ED; Frank CS; Black T; Jadhav PD; Holbrook LA; Laprairie RB
Sci Rep; 2020 Nov; 10(1):20405. PubMed ID: 33230154
[TBL] [Abstract][Full Text] [Related]
39. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro.
Milian L; Mata M; Alcacer J; Oliver M; Sancho-Tello M; Martín de Llano JJ; Camps C; Galbis J; Carretero J; Carda C
PLoS One; 2020; 15(2):e0228909. PubMed ID: 32049991
[TBL] [Abstract][Full Text] [Related]
40. At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction.
Montecucco F; Di Marzo V
Trends Pharmacol Sci; 2012 Jun; 33(6):331-40. PubMed ID: 22503477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
